Publications
Found 21 results
Filters: Author is J. Zhu [Clear All Filters]
, ,
“Association of the PPARγ2 Pro12Ala polymorphism with increased risk of cardiovascular diseases”, vol. 14, pp. 18662-18674, 2015.
, “Clinical features and treatment of endophthalmitis after cataract surgery”, vol. 14, pp. 6617-6624, 2015.
, “Cloning and expression analysis of a heat shock protein 90 β isoform gene from the gills of Wuchang bream (Megalobrama amblycephala Yih) subjected to nitrite stress”, vol. 14, pp. 3036-3051, 2015.
, “Evaluation of the function status of the ulnar nerve in carpal tunnel syndrome”, vol. 14, pp. 3680-3686, 2015.
, “Expression and significance of myeloid differentiation factor 88 in non-small cell lung carcinoma and normal paracancerous tissues”, vol. 14, pp. 14239-14245, 2015.
, “Expression of TRAIL and its receptor DR5 and their significance in acute leukemia cells”, vol. 14, pp. 18562-18568, 2015.
, “Identification of copy number variation in the gene for autosomal dominant optic atrophy, OPA1, in a Chinese pedigree”, vol. 14, pp. 10961-10972, 2015.
, “Lack of association between rare mutations of the SIAE gene and rheumatoid arthritis in a Han Chinese population”, vol. 14, pp. 14162-14168, 2015.
, “Overexpression of EsMcsu1 from the halophytic plant Eutrema salsugineum promotes abscisic acid biosynthesis and increases drought resistance in alfalfa (Medicago sativa L.)”, vol. 14, pp. 17204-17218, 2015.
, “VKORC1 rs2359612 and rs9923231 polymorphisms correlate with high risks of cardiovascular and cerebrovascular diseases”, vol. 14, pp. 14731-14744, 2015.
, “Correlation between MTP -493G>T polymorphism and non-alcoholic fatty liver disease risk: a meta-analysis”, vol. 13, pp. 10150-10161, 2014.
, , “Age-dependent expression of the BPI gene in Sutai piglets”, vol. 12, pp. 2120-2126, 2013.
, “Bicluster and regulatory network analysis of differentially expressed genes in adenocarcinoma and squamous cell carcinoma”, vol. 12, pp. 1710-1719, 2013.
, “Lack of association of IL-2RA and IL-2RB polymorphisms with rheumatoid arthritis in a Han Chinese population”, vol. 12, pp. 581-586, 2013.
, Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
http://dx.doi.org/10.1002/art.1780310302
PMid:3358796
Danoy P, Wei M, Johanna H, Jiang L, et al. (2011). Association of variants in MMEL1 and CTLA4 with rheumatoid arthritis in the Han Chinese population. Ann. Rheum. Dis. 70: 1793-1797.
http://dx.doi.org/10.1136/ard.2010.144576
PMid:21784728
Firestein GS (2003). Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
http://dx.doi.org/10.1038/nature01661
PMid:12748655
Foster MW and Freeman WL (1998). Naming names in human genetic variation research. Genome Res. 8: 755-757.
PMid:9724320
Hardy J and Singleton A (2009). Genomewide association studies and human disease. N. Engl. J. Med. 360: 1759-1768.
http://dx.doi.org/10.1056/NEJMra0808700
PMid:19369657 PMCid:3422859
Hinks A, Ke X, Barton A, Eyre S, et al. (2009). Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum. 60: 251-257.
http://dx.doi.org/10.1002/art.24187
PMid:19116909 PMCid:2963023
Isaacs JD (2010). The changing face of rheumatoid arthritis: sustained remission for all? Nat. Rev. Immunol. 10: 605-611.
http://dx.doi.org/10.1038/nri2804
PMid:20651747
Kochi Y, Suzuki A, Yamada R and Yamamoto K (2010). Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis. Nat. Rev. Rheumatol. 6: 290-295.
http://dx.doi.org/10.1038/nrrheum.2010.23
PMid:20234359
Kurreeman FA, Daha NA, Chang M, Catanese JJ, et al. (2009). Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann. Rheum. Dis. 68: 1789-1790.
http://dx.doi.org/10.1136/ard.2008.106393
PMid:19822714
Malek TR (2008). The biology of interleukin-2. Annu. Rev. Immunol. 26: 453-479.
http://dx.doi.org/10.1146/annurev.immunol.26.021607.090357
PMid:18062768
Mori M, Yamada R, Kobayashi K, Kawaida R, et al. (2005). Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J. Hum. Genet. 50: 264-266.
http://dx.doi.org/10.1007/s10038-005-0246-8
PMid:15883854
Morris JC and Waldmann TA (2000). Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. 59 (Suppl 1): i109-i114.
http://dx.doi.org/10.1136/ard.59.suppl_1.i109
PMid:11053100 PMCid:1766615
Plenge RM (2009). Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. Curr. Opin. Rheumatol. 21: 262-271.
http://dx.doi.org/10.1097/BOR.0b013e32832a2e2d
PMid:19365266
Silman AJ and Pearson JE (2002). Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4 (Suppl 3): S265-S272.
http://dx.doi.org/10.1186/ar578
PMid:12110146 PMCid:3240153
Vella A, Cooper JD, Lowe CE, Walker N, et al. (2005). Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76: 773-779.
http://dx.doi.org/10.1086/429843
PMid:15776395 PMCid:1199367
“RXR agonists inhibit high glucose-induced upregulation of inflammation by suppressing activation of the NADPH oxidase-nuclear factor-κB pathway in human endothelial cells”, vol. 12, pp. 6692-6707, 2013.
, “Significance of Bcl10 gene mutations in the clinical diagnosis of MALT-type ocular adnexal lymphoma in the Chinese population”, vol. 12, pp. 1194-1204, 2013.
, Coupland SE (2004). Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines. Ophthalmologe 101: 197-215.
http://dx.doi.org/10.1007/s00347-003-0854-7
PMid:15046030
Du MQ (2011). MALT lymphoma: many roads lead to nuclear factor-kappab activation. Histopathology 58: 26-38.
http://dx.doi.org/10.1111/j.1365-2559.2010.03699.x
PMid:21261681
Du MQ, Peng H, Liu H, Hamoudi RA, et al. (2000). BCL10 gene mutation in lymphoma. Blood 95: 3885-3890.
PMid:10845924
Garrison JB, Samuel T and Reed JC (2009). TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 28: 1584-1593.
http://dx.doi.org/10.1038/onc.2009.17
PMid:19234489
Hamoudi RA, Appert A, Ye H, Ruskone-Fourmestraux A, et al. (2010). Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 24: 1487-1497.
http://dx.doi.org/10.1038/leu.2010.118
PMid:20520640
Hosokawa Y and Seto M (2004). Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma. Int. J. Hematol. 80: 215-223.
http://dx.doi.org/10.1532/IJH97.04101
PMid:15540895
Kingeter LM and Schaefer BC (2010). Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives? Cell Signal. 22: 9-22.
http://dx.doi.org/10.1016/j.cellsig.2009.09.033
PMid:19772915 PMCid:2766428
Marcus R (2007). Pathogenesis of MALT lymphoma: implications for risk stratification and therapy. Leuk. Lymphoma 48: 2087-2088.
http://dx.doi.org/10.1080/10428190701713663
PMid:17990172
McKelvie PA (2010). Ocular adnexal lymphomas: a review. Adv. Anat. Pathol. 17: 251-261.
http://dx.doi.org/10.1097/PAP.0b013e3181e4abdb
PMid:20574170
Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, et al. (2011). Primary follicular lymphoma of the gastrointestinal tract. Am. J. Surg. Pathol. 35: 1255-1263.
http://dx.doi.org/10.1097/PAS.0b013e318224e661
PMid:21836483
Prasad S, Ravindran J and Aggarwal BB (2010). NF-kappaB and cancer: how intimate is this relationship. Mol. Cell Biochem. 336: 25-37.
http://dx.doi.org/10.1007/s11010-009-0267-2
PMid:19823771 PMCid:3148942
Rohatiner A, d'Amore F, Coiffier B, Crowther D, et al. (1994). Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann. Oncol. 5: 397-400.
PMid:8075046
Rosebeck S, Lucas PC and McAllister-Lucas LM (2011). Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol. 7: 613-617.
http://dx.doi.org/10.2217/fon.11.35
PMid:21568677 PMCid:3124218
Sagaert X, De Wolf-Peeters C, Noels H and Baens M (2007). The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21: 389-396.
http://dx.doi.org/10.1038/sj.leu.2404517
PMid:17230229
Sun W and Yang J (2010). Molecular basis of lysophosphatidic acid-induced NF-kappaB activation. Cell Signal. 22: 1799-1803.
http://dx.doi.org/10.1016/j.cellsig.2010.05.007
PMid:20471472 PMCid:2939192
Thieblemont C, Bastion Y, Berger F, Rieux C, et al. (1997). Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J. Clin. Oncol. 15: 1624-1630.
PMid:9193362
Willis TG, Jadayel DM, Du MQ, Peng H, et al. (1999). Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96: 35-45.
http://dx.doi.org/10.1016/S0092-8674(00)80957-5
Wu CJ and Ashwell JD (2008). NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. U. S. A. 105: 3023-3028.
http://dx.doi.org/10.1073/pnas.0712313105
PMid:18287044 PMCid:2268578
Ye H, Gong L, Liu H, Hamoudi RA, et al. (2005). MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J. Pathol. 205: 293-301.
http://dx.doi.org/10.1002/path.1715
PMid:15682443
Zhou H, Wertz I, O'Rourke K, Ultsch M, et al. (2004). Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427: 167-171.
http://dx.doi.org/10.1038/nature02273
PMid:14695475
“A novel NF1 mutation in a Chinese patient with giant café-au-lait macule in neurofibromatosis type 1 associated with a malignant peripheral nerve sheath tumor and bone abnormality”, vol. 11, pp. 2972-2978, 2012.
,
Bausch B, Borozdin W, Mautner VF, Hoffmann MM, et al. (2007). Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J. Clin. Endocrinol. Metab. 92: 2784-2792.
http://dx.doi.org/10.1210/jc.2006-2833
PMid:17426081
Bottillo I, Ahlquist T, Brekke H, Danielsen SA, et al. (2009). Germline and somatic NF1 mutations in sporadic and NF1- associated malignant peripheral nerve sheath tumours. J. Pathol. 217: 693-701.
http://dx.doi.org/10.1002/path.2494
PMid:19142971
Brems H, Beert E, de RT and Legius E (2009). Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 10: 508-515.
http://dx.doi.org/10.1016/S1470-2045(09)70033-6
Cai Y, Fan Z, Liu Q, Li J, et al. (2005). Two novel mutations of the NF1 gene in Chinese Han families with type 1 neurofibromatosis. J. Dermatol. Sci. 39: 125-127.
http://dx.doi.org/10.1016/j.jdermsci.2005.05.003
PMid:16005615
Cichowski K and Jacks T (2001). NF1 tumor suppressor gene function: narrowing the GAP. Cell 104: 593-604.
http://dx.doi.org/10.1016/S0092-8674(01)00245-8
Erdi H, Boyvat A and Calikoglu E (1999). Giant cafe au lait spot in a patient with neurofibromatosis. Acta Derm. Venereol. 79: 496.
http://dx.doi.org/10.1080/000155599750010157
PMid:10598783
Evans DG, Baser ME, McGaughran J, Sharif S, et al. (2002). Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39: 311-314.
http://dx.doi.org/10.1136/jmg.39.5.311
PMid:12011145 PMCid:1735122
Ferner RE and Gutmann DH (2002). International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 62: 1573-1577.
PMid:11894862
Gutmann DH, Aylsworth A, Carey JC, Korf B, et al. (1997). The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278: 51-57.
http://dx.doi.org/10.1001/jama.1997.03550010065042
PMid:9207339
Heim RA, Kam-Morgan LN, Binnie CG, Corns DD, et al. (1995). Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Hum. Mol. Genet. 4: 975-981.
http://dx.doi.org/10.1093/hmg/4.6.975
PMid:7655472
Huson SM, Harper PS and Compston DA (1988). Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111: 1355-1381.
http://dx.doi.org/10.1093/brain/111.6.1355
PMid:3145091
Kar M, Deo SV, Shukla NK, Malik A, et al. (2006). Malignant peripheral nerve sheath tumors (MPNST)-clinicopathological study and treatment outcome of twenty-four cases. World J. Surg. Oncol. 4: 55.
http://dx.doi.org/10.1186/1477-7819-4-55
PMid:16923196 PMCid:1560134
Lakkis MM, Golden JA, O'Shea KS and Epstein JA (1999). Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects. Dev. Biol. 212: 80-92.
http://dx.doi.org/10.1006/dbio.1999.9327
PMid:10419687
Messiaen L, Vogt J, Bengesser K, Fu C, et al. (2011). Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum. Mutat. 32: 213-219.
http://dx.doi.org/10.1002/humu.21418
PMid:21280148
Origone P, De LA, Bellini C, Buccino A, et al. (2002). Ten novel mutations in the human neurofibromatosis type 1 (NF1) gene in Italian patients. Hum. Mutat. 20: 74-75.
http://dx.doi.org/10.1002/humu.9039
PMid:12112660
Rasmussen SA and Friedman JM (2000). NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 151: 33-40.
http://dx.doi.org/10.1093/oxfordjournals.aje.a010118
PMid:10625171
Shah KN (2010). The diagnostic and clinical significance of cafe-au-lait macules. Pediatr. Clin. North Am. 57: 1131-1153.
http://dx.doi.org/10.1016/j.pcl.2010.07.002
PMid:20888463
Thappa DM, Jeevankumar B and Karthikeyan K (2001). Giant cafe-au-lait macule in neurofibromatosis type 1. J. Dermatol. 28: 60-61.
PMid:11280470
Upadhyaya M, Osborn MJ, Maynard J, Kim MR, et al. (1997). Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum. Genet. 99: 88-92.
http://dx.doi.org/10.1007/s004390050317
PMid:9003501
Upadhyaya M, Kluwe L, Spurlock G, Monem B, et al. (2008). Germline and somatic NF1 gene mutation spectrum in NF1- associated malignant peripheral nerve sheath tumors (MPNSTs). Hum. Mutat. 29: 74-82.
http://dx.doi.org/10.1002/humu.20601
PMid:17960768
Yang CC, Happle R, Chao SC, Yu-Yun LJ, et al. (2008). Giant cafe-au-lait macule in neurofibromatosis 1: a type 2 segmental manifestation of neurofibromatosis 1? J. Am. Acad. Dermatol. 58: 493-497.
http://dx.doi.org/10.1016/j.jaad.2007.03.013
PMid:18280349
Zhang W, Rhodes SD, Zhao L, He Y, et al. (2011). Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone 48: 1378-1387.
http://dx.doi.org/10.1016/j.bone.2011.03.760
PMid:21439418
“Lack of an association between -308G>A polymorphism of the TNF-α gene and liver cirrhosis risk based on a meta-analysis”, vol. 10, pp. 2765-2774, 2011.
, Bahr MJ, el Menuawy M, Boeker KH, Musholt PB, et al. (2003). Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int. 23: 420-425.
http://dx.doi.org/10.1111/j.1478-3231.2003.00873.x
PMid:14986816
Bataller R, North KE and Brenner DA (2003). Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37: 493-503.
http://dx.doi.org/10.1053/jhep.2003.50127
PMid:12601343
Cha C and Dematteo RP (2005). Molecular mechanisms in hepatocellular carcinoma development. Best Pract. Res. Clin. Gastroenterol. 19: 25-37.
http://dx.doi.org/10.1016/j.bpg.2004.11.005
Chan HL, Tse AM, Chim AM, Wong VW, et al. (2008). Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. J. Gastroenterol. Hepatol. 23: 783-789.
http://dx.doi.org/10.1111/j.1440-1746.2007.05110.x
PMid:17645476
Chen YQ, Lin JS, Tian DY and Liang KH (2003). Study on the association between the promoter polymorphism of TNF gene and cirrhosis. World J. Infect. 3: 186-190.
Choi J and Ou JH (2006). Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G847-G851.
http://dx.doi.org/10.1152/ajpgi.00522.2005
PMid:16603728
Chuang E, Del Vecchio A, Smolinski S, Song XY, et al. (2004). Biomedicines to reduce inflammation but not viral load in chronic HCV-what’s the sense? Trends Biotechnol. 22: 517-523.
http://dx.doi.org/10.1016/j.tibtech.2004.08.011
PMid:15450745
Commins SP, Borish L and Steinke JW (2010). Immunologic messenger molecules: cytokines, interferons, and chemokines. J. Allergy Clin. Immunol. 125: S53-S72.
http://dx.doi.org/10.1016/j.jaci.2009.07.008
PMid:19932918
Constantini PK, Wawrzynowicz-Syczewska M, Clare M, Boron-Kaczmarska A, et al. (2002). Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 22: 404-412.
http://dx.doi.org/10.1034/j.1600-0676.2002.01553.x
Cua IH, Hui JM, Bandara P, Kench JG, et al. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46: 66-73.
http://dx.doi.org/10.1002/hep.21703
PMid:17596870
Cuenca J, Perez CA, Aguirre AJ, Schiattino I, et al. (2001). Genetic polymorphism at position-308 in the promoter region of the tumor necrosis factor (TNF): implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population. Biol. Res. 34: 237-241.
http://dx.doi.org/10.4067/S0716-97602001000300011
PMid:11715861
Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, et al. (2005). Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr. Med. Res. Opin. 21: 527-534.
http://dx.doi.org/10.1185/030079905X38141
PMid:15899101
Falasca K, Ucciferri C, Dalessandro M, Zingariello P, et al. (2006). Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36: 144-150.
PMid:16682509
Fan LY, Zhong RQ, Tu XQ, Pfeiffer T, et al. (2004). Genetic association of tumor necrosis factor (TNF)-alpha polymorphisms with primary biliary cirrhosis and autoimmune liver diseases in a Chinese population. Zhonghua Gan Zang Bing Za Zhi 12: 160-162.
PMid:15059302
Friedman SL (2010). Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7: 425-436.
http://dx.doi.org/10.1038/nrgastro.2010.97
Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, et al. (1999). Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J. Hepatol. 31: 242-247.
http://dx.doi.org/10.1016/S0168-8278(99)80220-7
Hajeer AH and Hutchinson IV (2000). TNF-alpha gene polymorphism: clinical and biological implications. Microsc. Res. Tech. 50: 216-228.
http://dx.doi.org/10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q
Hajeer AH and Hutchinson IV (2001). Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum. Immunol. 62: 1191-1199.
http://dx.doi.org/10.1016/S0198-8859(01)00322-6
Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558.
http://dx.doi.org/10.1002/sim.1186
PMid:12111919
Jeng JE, Tsai JF, Chuang LY, Ho MS, et al. (2007). Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 9: 987-992.
http://dx.doi.org/10.1593/neo.07781
PMid:18030367
Jiang ZL, Zhang W, Zhang H and Liu YB (2009). Relationship between TNF-alpha, TGF-beta1 and IL-10 genetic polymorphisms and post- hepatitis B cirrhosis. Shi Jie Hua Ren Xiao Hua 17: 3263-3268.
Jones DE, Watt FE, Grove J, Newton JL, et al. (1999). Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J. Hepatol. 30: 232-236.
http://dx.doi.org/10.1016/S0168-8278(99)80067-1
Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, et al. (2010). Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 52: 223-229.
http://dx.doi.org/10.1002/hep.23667
PMid:20578265 PMCid:2922843
Kamal SM, Turner B, He Q, Rasenack J, et al. (2006). Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43: 771-779.
http://dx.doi.org/10.1002/hep.21117
PMid:16557547
Li Y, Chang M, Abar O, Garcia V, et al. (2009). Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J. Hepatol. 51: 750-757.
http://dx.doi.org/10.1016/j.jhep.2009.04.027
PMid:19586676 PMCid:2883297
Lim YS and Kim WR (2008). The global impact of hepatic fibrosis and end-stage liver disease. Clin. Liver Dis. 12: 733- 46, vii.
http://dx.doi.org/10.1016/j.cld.2008.07.007
PMid:18984463
Mallat A, Hezode C and Lotersztajn S (2008). Environmental factors as disease accelerators during chronic hepatitis C. J. Hepatol. 48: 657-665.
http://dx.doi.org/10.1016/j.jhep.2008.01.004
PMid:18279998
Nguyen-Khac E, Houchi H, Daoust M, Dupas JL, et al. (2008). The -308 TNFalpha gene polymorphism in severe acute alcoholic hepatitis: identification of a new susceptibility marker. Alcohol. Clin. Exp. Res. 32: 822-828.
http://dx.doi.org/10.1111/j.1530-0277.2008.00629.x
PMid:18336639
Niro GA, Poli F, Andriulli A, Bianchi I, et al. (2009). TNF-alpha polymorphisms in primary biliary cirrhosis: a northern and southern Italian experience. Ann. N. Y. Acad. Sci. 1173: 557-563.
http://dx.doi.org/10.1111/j.1749-6632.2009.04741.x
PMid:19758199
Oo YH, Hubscher SG and Adams DH (2010). Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol. Int. 4: 475-493.
http://dx.doi.org/10.1007/s12072-010-9183-5
PMid:20827405 PMCid:2900560
Pastor IJ, Laso FJ, Romero A and Gonzalez-Sarmiento R (2005). -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol. Clin. Exp. Res. 29: 1928-1931.
http://dx.doi.org/10.1097/01.alc.0000187595.19324.ca
Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680.
http://dx.doi.org/10.1001/jama.295.6.676
PMid:16467236
Poynard T, Mathurin P, Lai CL, Guyader D, et al. (2003). A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 38: 257-265.
http://dx.doi.org/10.1016/S0168-8278(02)00413-0
Schwabe RF and Brenner DA (2006). Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G583-G589.
http://dx.doi.org/10.1152/ajpgi.00422.2005
PMid:16537970
Tahara T, Shibata T, Nakamura M, Yamashita H, et al. (2009). Effect of polymorphisms in the 3’ untranslated region (3’- UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Mol. Carcinog. 48: 1030-1037.
http://dx.doi.org/10.1002/mc.20554
PMid:19496079
Tanaka A, Quaranta S, Mattalia A, Coppel R, et al. (1999). The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J. Hepatol. 30: 826-829.
http://dx.doi.org/10.1016/S0168-8278(99)80135-4
Thimme R, Wieland S, Steiger C, Ghrayeb J, et al. (2003). CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77: 68-76.
http://dx.doi.org/10.1128/JVI.77.1.68-76.2003
PMid:12477811 PMCid:140637
Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, et al. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835.
http://dx.doi.org/10.1097/EDE.0b013e3181577511
PMid:18049195
Wilson AG, di Giovine FS, Blakemore AI and Duff GW (1992). Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by NcoI restriction of PCR product. Hum. Mol. Genet. 1: 353.
http://dx.doi.org/10.1093/hmg/1.5.353
PMid:1363876
Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137.
http://dx.doi.org/10.1002/gepi.20048
PMid:15593093